Skip to main content

Home

Press Releases

Press Releases
February 14, 2020

Today, Congressman Kevin McCarthy and Congressman David Schweikert (AZ-06) sent a letter to the U.S. Department of Health and Human Services and the U.S. Food and Drug Administration (FDA) requesting the FDA hold public workshops to help with the development of Valley Fever drugs and vaccines.


November 13, 2019

WASHINGTON, DC – Today, Co-Chairs of the Congressional Valley Fever Task Force David Schweikert (AZ-06) and Kevin McCarthy (CA-23) joined in celebrating Valley Fever Awareness Week in Arizona.


May 22, 2019

Washington, D.C. – Today, Congressman and Congressional Valley Fever Task Force Co-Chair Kevin McCarthy, U.S. Senator Martha McSally (R-AZ), Congressman and Congressional Valley Fever Task Force Co-Chair David Schweikert (AZ-06), Congresswoman Karen Bass (CA-37), Congressman Greg Stanton (AZ-09), and U.S. Senator Kyrsten Sinema (D-AZ), introduced H.R. 2858 and S. 1567, the Finding Orphan-disease Remedies with Antifungal Research and Development (FORWARD) Act .


July 26, 2018

Today, Congressman Kevin McCarthy, Co-Chairman of the Congressional Valley Fever Task Force, introduced H.R. 6562, the bipartisan FORWARD Act with fellow Co-Chairman Congressman David Schweikert (AZ-6) and Task Force Members Congresswoman Martha McSally (AZ-2), Congresswoman Karen Bass (CA-37), and Congresswoman Kyrsten Sinema (AZ-9). This legislation would strengthen research and help advance treatment and vaccine development for Coccidioidomycosis, commonly known as Valley Fever, as well as other orphan endemic fungal diseases.


May 4, 2018

Today, Congressman McCarthy, as Co-Chair of the Congressional Valley Fever Task Force, along with 16 of his colleagues in the House, sent a letter to National Institutes of Health (NIH) Director Francis Collins in support of grant funding to help move a Valley Fever diagnostic tool into primary care settings, such as the family doctor's office. Currently, Immuno-Mycologics, Inc. (IMMY) has a rapid diagnostic tool, which consists of a dipstick test to detect the presence of Valley Fever antibodies in human blood in as little as 30 minutes.


June 11, 2014
Washington, DC - Chairman of the Congressional Valley Fever Task Force, Rep. Kevin McCarthy (CA-23) and Co-Chairman, Rep. David Schweikert (AZ-06) released the following statement on the Food and Drug Administration’s (FDA) decision to include the Coccidioides species, known to cause what is commonly referred to as Valley Fever, on a list of Qualifying Pathogens it developed as required by the Generating Antibiotic Incentives Now (GAIN) provisions of Public Law 112-144:

Our Chairs

Speaker Kevin McCarthy

Image
Speaker Kevin McCarthy headshot
Kevin McCarthy proudly serves California’s 20th district and is serving as the 55th Speaker of the U.S. House of Representatives. Kevin was first elected to Congress in 2006 and is a native of Bakersfield and a fourth-generation Kern County resident. The grandson of a cattle rancher and the son of a firefighter, Kevin grew up a working-class family and is committed to preserving and promoting the American dream for hardworking Americans.

Rep. David Schweikert

Image
David Schweikert headshot

David Schweikert is serving his seventh term in the United States Congress. He holds a seat on the Ways and Means Committee and is the current Chairman of the Oversight Subcommittee. He is also the Lead House Republican on the bicameral Joint Economic Committee, co-chairs the Valley Fever Task Force with Speaker Kevin McCarthy, and is the Republican Co-Chair of the Blockchain Caucus, Telehealth Caucus, Singapore Caucus, and the Caucus on Access to Capital and Credit.